Pharmacogenetic Implications Of The Enos Polymorphisms For Cardiovascular Action Drugs

dc.creatorSilva P.S.
dc.creatorLacchini R.
dc.creatorde Aguiar Gomes V.
dc.creatorTanus-Santos J.E.
dc.date2011
dc.date2015-06-30T20:25:30Z
dc.date2015-11-26T14:49:14Z
dc.date2015-06-30T20:25:30Z
dc.date2015-11-26T14:49:14Z
dc.date.accessioned2018-03-28T22:00:11Z
dc.date.available2018-03-28T22:00:11Z
dc.identifier
dc.identifierArquivos Brasileiros De Cardiologia. , v. 96, n. 2, p. e27 - e34, 2011.
dc.identifier0066782X
dc.identifier10.1590/S0066-782X2011000200017
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-79953296501&partnerID=40&md5=7632b023b43a615003de0a96f0c9fb8c
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/107875
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/107875
dc.identifier2-s2.0-79953296501
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1253843
dc.descriptionThe pharmacogenetics is one of the most promising fields of medicine. The conclusion of the Genome Project allowed this field to start discovering complex factors modulating the response to drugs, and new technologies are close a great expansion of the area. The cardiovascular diseases are currently among the major causes of hospitalizations and death, and have been the target of a large part of genetic studies of complex diseases. Parallel to the susceptibility to disease markers identification, it is necessary to investigate how different genetic profiles can change the responses to the currently used drugs. The biological system that controls the endothelial production of the nitric oxide has been one of the greatest targets in the pharmacological responses to the drugs used in the cardiovascular diseases therapy. This review aims at approaching the current knowledge on interaction among the genetic variations of eNOS and the pharmacological responses to the drugs used in the cardiovascular system.
dc.description96
dc.description2
dc.descriptione27
dc.descriptione34
dc.descriptionLander, E.S., Linton, L.M., Birren, B., Nusbaum, C., Zody, M.C., Baldwin, J., Initial sequencing and analysis of the human genome (2001) Nature, 409 (6822), pp. 860-921
dc.descriptionThe International HapMap Project (2003) Nature, 426 (6968), pp. 789-796
dc.descriptionEvans, W.E., McLeod, H.L., Pharmacogenomics--drug disposition, drug targets, and side effects (2003) N Engl J Med, 348 (6), pp. 538-549
dc.descriptionGurwitz, D., McLeod, H.L., Genome-wide association studies: Powerful tools for improving drug safety and efficacy (2009) Pharmacogenomics, 10 (2), pp. 157-159
dc.descriptionBudnitz, D.S., Pollock, D.A., Weidenbach, K.N., Mendelsohn, A.B., Schroeder, T.J., Annest, J.L., National surveillance of emergency department visits for outpatient adverse drug events (2006) JAMA, 296 (15), pp. 1858-1866
dc.descriptionPirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients (2004) BMJ, 329 (7456), pp. 15-19
dc.descriptionPeters, E.J., McLeod, H.L., Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants (2008) Pharmacogenomics, 9 (11), pp. 1573-1577
dc.descriptionBader, J.S., Systems approaches for pharmacogenetics and pharmacogenomics (2008) Pharmacogenomics, 9 (3), pp. 257-262
dc.descriptionTopol, E.J., Frazer, K.A., The resequencing imperative (2007) Nat Genet, 39 (4), pp. 439-440
dc.descriptionDorn, G.W., Cresci, S., The mechanistic imperative for pharmacogenomics (2008) Pharmacogenomics, 9 (7), pp. 801-803
dc.descriptionMarsh, S., Pharmacogenetics: Global clinical markers (2008) Pharmacogenomics, 9 (4), pp. 371-373
dc.descriptionLacchini, R., Sabha, M., Coeli, F.B., Favero, F.F., Yugar-Toledo, J., Izidoro-Toledo, T.C., T allele of -344C/T polymorphism in aldosterone synthase gene is not associated with resistant hypertension (2009) Hypertens Res, 32 (2), pp. 159-162
dc.descriptionSandrim, V.C., Palei, A.C., Cavalli, R.C., Araujo, F.M., Ramos, E.S., Duarte, G., eNOS Haplotypes associated with gestational hypertension or preeclampsia (2008) Pharmacogenomics, 9 (10), pp. 1467-1473
dc.descriptionMoncada, S., Higgs, A., The L-arginine-nitric oxide pathway (1993) N Engl J Med, 329 (27), pp. 2002-2012
dc.descriptionKiechle, F.L., Malinski, T., Nitric oxide: Biochemistry, pathophysiology, and detection (1993) Am J Clin Pathol, 100 (5), pp. 567-575
dc.descriptionCooke, J.P., Dzau, V.J., Nitric oxide synthase: Role in the genesis of vascular disease (1997) Annu Rev Med, 48, pp. 489-509
dc.descriptionDudzinski, D.M., Igarashi, J., Greif, D., Michel, T., The regulation and pharmacology of endothelial nitric oxide synthase (2006) Annu Rev Pharmacol Toxicol, 46, pp. 235-276
dc.descriptionPerticone, F., Ceravolo, R., Pujia, A., Ventura, G., Iacopino, S., Scozzafava, A., Prognostic significance of endothelial dysfunction in hypertensive patients (2001) Circulation, 104 (2), pp. 191-196
dc.descriptionSandrim, V.C., Palei, A.C., Metzger, I.F., Gomes, V.A., Cavalli, R.C., Tanus-Santos, J.E., Nitric oxide formation is inversely related to serum levels of antiangiogenic factors soluble fms-like tyrosine kinase-1 and soluble endogline in preeclampsia (2008) Hypertension, 52 (2), pp. 402-407
dc.descriptionGomes, V.A., Casella-Filho, A., Chagas, A.C., Tanus-Santos, J.E., Enhanced concentrations of relevant markers of nitric oxide formation after exercise training in patients with metabolic syndrome (2008) Nitric Oxide, 19 (4), pp. 345-350
dc.descriptionGryglewski, R.J., Palmer, R.M., Moncada, S., Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor (1986) Nature, 320 (6061), pp. 454-456
dc.descriptionVasquez-Vivar, J., Kalyanaraman, B., Martasek, P., Hogg, N., Masters, B.S., Karoui, H., Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors (1998) Proc Natl Acad Sci U S A, 95 (16), pp. 9220-9225
dc.descriptionMason, R.P., Cockcroft, J.R., Targeting nitric oxide with drug therapy (2006) J Clin Hypertens (Greenwich), 8 (12 suppl 4), pp. 40-52
dc.descriptionLiao, J.K., Laufs, U., Pleiotropic effects of statins (2005) Annu Rev Pharmacol Toxicol, 45, pp. 89-118
dc.descriptionPalinski, W., New evidence for beneficial effects of statins unrelated to lipid lowering (2001) Arterioscler Thromb Vasc Biol, 21 (1), pp. 3-5
dc.descriptionSharma, J.N., Abbas, S.A., Effect of captopril in the presence of kinin B2 receptor antagonist on duration of survival after prolonged coronary artery ligation in hypertensive rats (2006) Methods Find Exp Clin Pharmacol, 28 (4), pp. 217-221
dc.descriptionCargnoni, A., Comini, L., Bernocchi, P., Bachetti, T., Ceconi, C., Curello, S., Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril (2001) Br J Pharmacol, 133 (1), pp. 145-153
dc.descriptionWiemer, G., Linz, W., Hatrik, S., Scholkens, B.A., Malinski, T., Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats (1997) Hypertension, 30 (5), pp. 1183-1190
dc.descriptionZhuo, J.L., Mendelsohn, F.A., Ohishi, M., Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease (2002) Hypertension, 39 (2 Pt 2), pp. 634-638
dc.descriptionSilvestre, J.S., Bergaya, S., Tamarat, R., Duriez, M., Boulanger, C.M., Levy, B.I., Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway (2001) Circ Res, 89 (8), pp. 678-683
dc.descriptionVeeravalli, K.K., Akula, A., Involvement of nitric oxide and prostaglandin pathways in the cardioprotective actions of bradykinin in rats with experimental myocardial infarction (2004) Pharmacol Res, 49 (1), pp. 23-29
dc.descriptionBachetti, T., Comini, L., Pasini, E., Cargnoni, A., Curello, S., Ferrari, R., Ace-inhibition with quinapril modulates the nitric oxide pathway in normotensive rats (2001) J Mol Cell Cardiol, 33 (3), pp. 395-403
dc.descriptionThai, H., Wollmuth, J., Goldman, S., Gaballa, M., Angiotensin subtype 1 rReceptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor (2003) J Pharmacol Exp Ther, 307 (3), pp. 1171-1178
dc.descriptionMason, R.P., Marche, P., Hintze, T.H., Novel vascular biology of third-generation L-type calcium channel antagonists: Ancillary actions of amlodipine (2003) Arterioscler Thromb Vasc Biol, 23 (12), pp. 2155-2163
dc.descriptionKobayashi, N., Yanaka, H., Tojo, A., Kobayashi, K., Matsuoka, H., Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats (1999) J Cardiovasc Pharmacol, 34 (2), pp. 173-181
dc.descriptionZineh, I., Pharmacogenetics of response to statins (2007) Curr Atheroscler Rep, 9 (3), pp. 187-194
dc.descriptionDavignon, J., Ganz, P., Role of endothelial dysfunction in atherosclerosis (2004) Circulation, 109 (23 suppl 1), pp. III27-III32
dc.descriptionWolfrum, S., Jensen, K.S., Liao, J.K., Endothelium-dependent effects of statins (2003) Arterioscler Thromb Vasc Biol, 23 (5), pp. 729-736
dc.descriptionLaufs, U., la Fata, V., Plutzky, J., Liao, J.K., Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors (1998) Circulation, 97 (12), pp. 1129-1135
dc.descriptionSumi, D., Hayashi, T., Thakur, N.K., Jayachandran, M., Asai, Y., Kano, H., A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action (2001) Atherosclerosis, 155 (2), pp. 347-357
dc.descriptionJackson, G., Treatment of erectile dysfunction in patients with cardiovascular disease: Guide to drug selection (2004) Drugs, 64 (14), pp. 1533-1545
dc.descriptionBivalacqua, T.J., Usta, M.F., Champion, H.C., Leungwattanakij, S., Dabisch, P.A., McNamara, D.B., Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats (2004) Int J Impot Res, 16 (1), pp. 21-29
dc.descriptionNagayama, T., Zhang, M., Hsu, S., Takimoto, E., Kass, D.A., Sustained soluble guanylate cyclase stimulation offsets nitric-oxide synthase inhibition to restore acute cardiac modulation by sildenafil (2008) J Pharmacol Exp Ther, 326 (2), pp. 380-387
dc.descriptionSenzaki, H., Smith, C.J., Juang, G.J., Isoda, T., Mayer, S.P., Ohler, A., Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure (2001) FASEB J, 15 (10), pp. 1718-1726
dc.descriptionMarsden, P.A., Heng, H.H., Scherer, S.W., Stewart, R.J., Hall, A.V., Shi, X.M., Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene (1993) J Biol Chem, 268 (23), pp. 17478-17488
dc.descriptionMiyahara, K., Kawamoto, T., Sase, K., Yui, Y., Toda, K., Yang, L.X., Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene (1994) Eur J Biochem, 223 (3), pp. 719-726
dc.descriptionCooke, G.E., Doshi, A., Binkley, P.F., Endothelial nitric oxide synthase gene: Prospects for treatment of heart disease (2007) Pharmacogenomics, 8 (12), pp. 1723-1734
dc.descriptionPereira, T.V., Rudnicki, M., Cheung, B.M., Baum, L., Yamada, Y., Oliveira, P.S., Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: Meta-analysis of 53 studies reveals evidence of publication bias (2007) J Hypertens, 25 (9), pp. 1763-1774
dc.descriptionSandrim, V.C., Palei, A.C., Cavalli, R.C., Araujo, F.M., Ramos, E.S., Duarte, G., Vascular endothelial growth factor genotypes and haplotypes are associated with pre-eclampsia but not with gestational hypertension (2009) Mol Hum Reprod, 15 (2), pp. 115-120
dc.descriptionNakayama, M., Yasue, H., Yoshimura, M., Shimasaki, Y., Ogawa, H., Kugiyama, K., T(-786)--> C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis (2000) Am J Cardiol, 86 (6), pp. 628-634
dc.descriptionMiyamoto, Y., Saito, Y., Nakayama, M., Shimasaki, Y., Yoshimura, T., Yoshimura, M., Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T-->C mutation associated with coronary spastic angina (2000) Hum Mol Genet, 9 (18), pp. 2629-2637
dc.descriptionNakayama, M., Yasue, H., Yoshimura, M., Shimasaki, Y., Kugiyama, K., Ogawa, H., T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm (1999) Circulation, 99 (22), pp. 2864-2870
dc.descriptionWang, X.L., Mahaney, M.C., Sim, A.S., Wang, J., Wang, J., Blangero, J., Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels (1997) Arterioscler Thromb Vasc Biol, 17 (11), pp. 3147-3153
dc.descriptionTsukada, T., Yokoyama, K., Arai, T., Takemoto, F., Hara, S., Yamada, A., Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans (1998) Biochem Biophys Res Commun, 245 (1), pp. 190-193
dc.descriptionZhang, M.X., Zhang, C., Shen, Y.H., Wang, J., Li, X.N., Chen, L., Effect of 27nt small RNA on endothelial nitric-oxide synthase expression (2008) Mol Biol Cell, 19 (9), pp. 3997-4005
dc.descriptionZhang, M.X., Zhang, C., Shen, Y.H., Wang, J., Li, X.N., Zhang, Y., Biogenesis of short intronic repeat 27-nucleotide small RNA from endothelial nitric-oxide synthase gene (2008) J Biol Chem, 283 (21), pp. 14685-14693
dc.descriptionCasas, J.P., Bautista, L.E., Humphries, S.E., Hingorani, A.D., Endothelial nitric oxide synthase genotype and ischemic heart disease: Meta-analysis of 26 studies involving 23028 subjects (2004) Circulation, 109 (11), pp. 1359-1365
dc.descriptionTanus-Santos, J.E., Desai, M., Deak, L.R., Pezzullo, J.C., Abernethy, D.R., Flockhart, D.A., Effects of endothelial nitric oxide synthase gene polymorphisms on platelet function, nitric oxide release, and interactions with estradiol (2002) Pharmacogenetics, 12 (5), pp. 407-413
dc.descriptionGodfrey, V., Chan, S.L., Cassidy, A., Butler, R., Choy, A., Fardon, T., The functional consequence of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene in young healthy volunteers (2007) Cardiovasc Drug Rev, 25 (3), pp. 280-288
dc.descriptionJoshi, M.S., Mineo, C., Shaul, P.W., Bauer, J.A., Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: Altered caveolar localization and impaired response to shear (2007) Faseb J, 21 (11), pp. 2655-2663
dc.descriptionCrawford, D.C., Nickerson, D.A., Definition and clinical importance of haplotypes (2005) Annu Rev Med, 56, pp. 303-320
dc.descriptionSandrim, V.C., Yugar-Toledo, J.C., Desta, Z., Flockhart, D.A., Moreno Jr., H., Tanus-Santos, J.E., Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy (2006) J Hypertens, 24 (12), pp. 2393-2397
dc.descriptionMetzger, I.F., Sertorio, J.T., Tanus-Santos, J.E., Modulation of nitric oxide formation by endothelial nitric oxide synthase gene haplotypes (2007) Free Radic Biol Med, 43 (6), pp. 987-992
dc.descriptionMetzger, I.F., Souza-Costa, D.C., Marroni, A.S., Nagassaki, S., Desta, Z., Flockhart, D.A., Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men (2005) Pharmacogenet Genomics, 15 (8), pp. 565-570
dc.descriptionAbe, K., Nakayama, M., Yoshimura, M., Nakamura, S., Ito, T., Yamamuro, M., Increase in the transcriptional activity of the endothelial nitric oxide synthase gene with fluvastatin: A relation with the -786T>C polymorphism (2005) Pharmacogenet Genomics, 15 (5), pp. 329-336
dc.descriptionNagassaki, S., Sertorio, J.T., Metzger, I.F., Bem, A.F., Rocha, J.B., Tanus-Santos, J.E., eNOS Gene T-786C polymorphism modulates atorvastatin-induced increase in blood nitrite (2006) Free Radic Biol Med, 41 (7), pp. 1044-1049
dc.descriptionSouza-Costa, D.C., Sandrim, V.C., Lopes, L.F., Gerlach, R.F., Rego, E.M., Tanus-Santos, J.E., Anti-inflammatory effects of atorvastatin: Modulation by the T-786C polymorphism in the endothelial nitric oxide synthase gene (2007) Atherosclerosis, 193 (2), pp. 438-444
dc.descriptionNagassaki, S., Herculano, R.D., Graeff, C.F., Tanus-Santos, J.E., eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity (2009) Eur J Clin Pharmacol, 65 (4), pp. 385-392
dc.descriptionKunnas, T.A., Lehtimaki, T., Laaksonen, R., Ilveskoski, E., Janatuinen, T., Vesalainen, R., Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: A placebo-controlled PET study (2002) J Mol Med, 80 (12), pp. 802-807
dc.descriptionTurner, S.T., Chapman, A.B., Schwartz, G.L., Boerwinkle, E., Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide (2003) Am J Hypertens, 16 (10), pp. 834-839
dc.descriptionLiljedahl, U., Karlsson, J., Melhus, H., Kurland, L., Lindersson, M., Kahan, T., A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response (2003) Pharmacogenetics, 13 (1), pp. 7-17
dc.descriptionChobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo Jr., J.L., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report (2003) JAMA, 289 (19), pp. 2560-2572
dc.descriptionJachymova, M., Horky, K., Bultas, J., Kozich, V., Jindra, A., Peleska, J., Association of the Glu298Asp polymorphism in the endothelial nitric oxide synthase gene with essential hypertension resistant to conventional therapy (2001) Biochem Biophys Res Commun, 284 (2), pp. 426-430
dc.descriptionEisenhardt, A., Sperling, H., Hauck, E., Porst, H., Stief, C., Rubben, H., ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction (2003) Urology, 62 (1), pp. 152-157
dc.languageen
dc.publisher
dc.relationArquivos Brasileiros de Cardiologia
dc.rightsaberto
dc.sourceScopus
dc.titlePharmacogenetic Implications Of The Enos Polymorphisms For Cardiovascular Action Drugs
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución